Short answer
Trevi Therapeutics, Inc. (TRVI) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results announced for quarter ended March 31, 2026.
Trevi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced for quarter ended March 31, 2026
- Full results and management commentary available in Exhibit 99.1 press release
- Disclosure furnished under Item 2.02, making results available to investors but requiring exhibit review for figures
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 net loss widened to $13.2M from $10.3M as R&D rose to $9.9M and G&A to $5.0M
- April stock offering generated approximately $162M net, extending expected cash runway into 2030
- First IPF-related chronic cough Phase 3 trial expected to start Q2 2026, with topline results targeted for first half 2028
- RCC Phase 2b trial planned for Q2 2026, while non-IPF ILD Phase 2b remains targeted for second half 2026
- FDA alignment and a European patent expected to expire in 2039 reduce development uncertainty and strengthen Haduvio’s potential positioning
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Trevi Therapeutics, Inc. 8-K filings
Get the next TRVI 8-K as it lands
Follow TRVI for push alerts, or ask the research agent what this filing means.